TherapeuticsMD amends CEO Walker's employment; enters consulting agreement with former CFO Donegan

TherapeuticsMD, Inc.

CEO Walker's base salary increased to $500k after Apr 15, 2023; receives $20,909 lump-sum bonus and 70,000 RSUs.
Enhanced severance: 18 months salary, 1.5x target bonus, 24 months COBRA, full equity vesting on termination without cause or for good reason.
Former interim CFO Donegan to provide consulting services as PFO/PAO via MCD Consulting; receives $100k signing fee, $50k/month, and 50,000 RSUs.
Consulting agreement anticipated to end March 31, 2023; if extended, hourly rate $205.28; additional $100k fee on termination.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michael Donegan

Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance

TXMD · TherapeuticsMD, Inc.

Effective: 2023-01-11
Filed: February 27, 2023, 6:59 PM ET

terminated that certain amended and restated employment agreement, dated November 24, 2020, by and between the Company and Mr. Michael Donegan, the Company’s former Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance.

Appointed (interim)

Michael Donegan

Principal Financial Officer and Principal Accounting Officer

TXMD · TherapeuticsMD, Inc.

Effective: 2023-02-21
Filed: February 27, 2023, 6:59 PM ET

Effective February 21, 2023, the Company entered into a General Consulting and Services Agreement (the “Consulting Agreement”) with MCD Consulting and Management Services, LLC (“MCD”), the manager of which is Mr. Donegan, the Company’s Principal Financial Officer (“PFO”) and Principal Accounting Officer (“PAO”) and former Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Donegan was terminated as Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance at TherapeuticsMD, Inc..

Action: terminated
Role: Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance

Exact text from the filing

terminated that certain amended and restated employment agreement, dated November 24, 2020, by and between the Company and Mr. Michael Donegan, the Company’s former Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Donegan was appointed as Principal Financial Officer and Principal Accounting Officer at TherapeuticsMD, Inc..

Action: appointed
Role: Principal Financial Officer and Principal Accounting Officer

Exact text from the filing

Effective February 21, 2023, the Company entered into a General Consulting and Services Agreement (the “Consulting Agreement”) with MCD Consulting and Management Services, LLC (“MCD”), the manager of which is Mr. Donegan, the Company’s Principal Financial Officer (“PFO”) and Principal Accounting Officer (“PAO”) and former Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance.

View on SEC.gov

TherapeuticsMD, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-050813

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.